REFERENCES
- Mannino D M. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002; 121: 121S–126S, [INFOTRIEVE], [CSA]
- Pauwels R A, Rabe K F. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613–620, [INFOTRIEVE], [CROSSREF], [CSA]
- Halpern M T, Stanford R H, Borker R. The burden of COPD in the U.S.A.: results from the confronting COPD survey. Respir Med 2003; 97C: S81–S89, [CROSSREF], [CSA]
- Chiba H, Abe S. The environmental risk factors for COPD—tobacco smoke, air pollution, chemicals. Nippon Rinsho 2003; 61: 2101–2106, [INFOTRIEVE], [CSA]
- Branden E, Koyi H, Gnarpe J, Gnarpe H, Tornling G. Chronic chlamydia pneumonia infection is a risk factor for the development of COPD. Respir Med 2005; 99: 20–26, [INFOTRIEVE], [CROSSREF], [CSA]
- Kornmann O, Beeh K M, Beier J, Geis U P, Ksoll M, Buhl R. Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the global initiative for obstructive lung disease. Respiration 2003; 70: 67–75, [INFOTRIEVE], [CROSSREF], [CSA]
- Britton M. The burden of COPD in the U.K.: results from the confronting COPD survey. Respir Med 2003; 97C: S71–S79, [CROSSREF], [CSA]
- Izquierdo J L. The burden of COPD in Spain: results from the confronting COPD survey. Respir Med 2003; 97C: S61–S69, [CROSSREF], [CSA]
- Wouters E F. The burden of COPD in The Netherlands: results from the confronting COPD survey. Respir Med 2003; 97C: S51–S59, [CROSSREF], [CSA]
- Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the confronting COPD survey. Respir Med 2003; 97C: S43–S50, [CROSSREF], [CSA]
- Piperno D, Huchon G, Pribil C, Boucot I, Similowski T. The burden of COPD in France: results from the confronting COPD survey. Respir Med 2003; 97C: S33–S42, [CROSSREF], [CSA]
- Chapman K R, Bourbeau J, Rance L. The burden of COPD in Canada: results from the confronting COPD survey. Respir Med 2003; 97C: S23–S31, [CROSSREF], [CSA]
- Sullivan S D, Ramsey S D, Lee T A. The economic burden of COPD. Chest 2000; 117: 5S–9S, [INFOTRIEVE], [CROSSREF], [CSA]
- Sullivan S D, Strassels S A. Health Economics. Asthma and COPD: Basic mechanisms and clinical management, P J Barnes, J M Drazen, S Rennard, N C Thomson. Academic Press, Amsterdam Boston 2002; 657–671
- Sullivan S D, Buist A S, Weiss K. Health outcomes assessment and economic evaluation in COPD: challenges and opportunities. Eur Respir J Suppl 2003; 41: 1s–3s, [INFOTRIEVE], [CROSSREF], [CSA]
- Eisner M D, Yelin E H, Trupin L, Blanc P D. The influence of chronic respiratory conditions on health status and work disability. Am J Public Health 2002; 92: 1506–1513, [INFOTRIEVE], [CSA]
- Tinkelman D, Corsello P. Chronic obstructive pulmonary disease: the impact occurs earlier than we think. Am J Manag Care 2003; 9: 767–771, [INFOTRIEVE], [CSA]
- Tinkelman D, Nordyke R J, Isonaka S, George D, Desfosses K, Nonikov D. The impact of chronic obstructive pulmonary disease on long-term disability costs. J Manag Care Pharm 2005; 11: 25–32, [INFOTRIEVE], [CSA]
- Ramsey S D, Sullivan S D. The burden of illness and economic evaluation for COPD. Eur Respir J Suppl 2003; 41: 29s–35s, [INFOTRIEVE], [CROSSREF], [CSA]
- Oostenbrink J B, Rutten-Van Molken M P. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med 2004; 98: 883–891, [INFOTRIEVE], [CROSSREF], [CSA]
- Andersson F, Borg S, Jansson S A, Jonsson A C, Ericsson A, Prutz C, Ronmark E, Lundback B. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96: 700–708, [INFOTRIEVE], [CROSSREF], [CSA]
- Strassels S A, Smith D H, Sullivan S D, Mahajan P S. The costs of treating COPD in the United States. Chest 2001; 119: 344–352, [INFOTRIEVE], [CROSSREF], [CSA]